Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
Sign Up to like & getrecommendations! Published in 2021 at "Oncoimmunology"
DOI: 10.1080/2162402x.2021.1943253
Abstract: ABSTRACT Background Pegylated arginine deiminase (ADI-PEG 20) is a metabolism-based strategy that depletes arginine, resulting in tumoral stress and cytotoxicity. Preclinically, ADI-PEG 20 modulates T-cell activity and enhances the therapeutic efficacy of programmed death-1 (PD-1)… read more here.
Keywords: pembrolizumab; peg; adi peg; pegylated arginine ... See more keywords